title: Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.
abstract: Artemisinin combination therapies eliminate immature Plasmodium falciparum gametocytes but not mature gametocytes, which may persist for up to 1 month posttreatment. A single dose of primaquine, which is inexpensive and effective against mature gametocytes, could be added to further reduce the potential for posttreatment parasite transmission. Currently, we have few data regarding the effectiveness or safety of doing so. We collected data from 21 therapeutic efficacy trials of the National Antimalarial Drug Resistance Monitoring System of India conducted during 2009 to 2010, wherein 9 sites used single-dose primaquine (0.75 mg/kg of body weight) administered on day 2 along with artesunate plus sulfadoxine-pyrimethamine (AS+SP) while 12 did not. We estimated the effect of primaquine on posttreatment gametocyte clearance and the total number of gametocyte-weeks as determined by microscopy. We compared the median area under the curve for gametocyte density and reported adverse events. One thousand three hundred thirty-five patients completed the antimalarial drug treatment. Adjusting for region, primaquine increased the rate of gametocyte clearance (hazard ratio, 1.9; 95% confidence interval [CI], 1.1 to 3.3), prevented 45% (95% CI, 19 to 62) of posttreatment gametocyte-weeks, and decreased the area under the gametocyte density curve over the 28-day follow-up compared to AS+SP alone (P value = 0.01). The results were robust to other adjustment sets, and the estimated effect of primaquine increased during sensitivity analysis on the measurement of exposure time. No serious adverse events were detected. In conclusion, the addition of primaquine to AS+SP was effective in reducing the posttreatment presence of P. falciparum gametocytes. Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as the first-line therapy.
authors.affiliation: School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
authors.forename: Naman K
authors.initials: NK
authors.lastname: Shah
authors.forename: Allan
authors.initials: A
authors.lastname: Schapira
authors.forename: Jonathan J
authors.initials: JJ
authors.lastname: Juliano
authors.forename: Bina
authors.initials: B
authors.lastname: Srivastava
authors.forename: Pia D M
authors.initials: PD
authors.lastname: MacDonald
authors.forename: Charles
authors.initials: C
authors.lastname: Poole
authors.forename: Anup
authors.initials: A
authors.lastname: Anvikar
authors.forename: Steven R
authors.initials: SR
authors.lastname: Meshnick
authors.forename: Neena
authors.initials: N
authors.lastname: Valecha
authors.forename: Neelima
authors.initials: N
authors.lastname: Mishra
mesh_terms: D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007194:India; D007223:Infant; D007231:Infant, Newborn; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology / Q000635:transmission; D008297:Male; D008875:Middle Aged; D018512:Parasitemia / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000187:drug effects*; D011319:Primaquine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055502:Secondary Prevention; D013413:Sulfadoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C578917:sulfadoxine-pyrimethamine-artesunate; D013413:Sulfadoxine; D011319:Primaquine; D011739:Pyrimethamine